Among the PTCL patients, the ORR was 46
Among the PTCL patients, the ORR was 46.7%, as well as the CRR was 20%. molecular research have revealed several different systems that drive the advancement of the malignancies and could be connected with level of resistance to therapies. Although recognized chemotherapeutic realtors and combos …